Probiotic Ingestion and Isoagglutinin Titers

NCT00891787 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-10-06

No results posted yet for this study

Summary

Background:

* Probiotics are oral food supplements containing live bacteria that may be beneficial to a person s digestion or general health. Probiotics are available as tablets, powder, or liquid supplements and are frequently used to supplement yogurt. They are available for purchase without prescription in most supermarkets.
* The bacteria in probiotic supplements commonly express sugar substances on their surface. These sugar substances are similar to group A and B blood group sugars, called antigens. These antigens determine a person s blood group. Researchers are studying the effect of probiotic supplements on the amount of blood group antibodies that are present in a person s blood.

Objectives:

* To determine whether taking oral probiotic supplements increases anti-A and anti-B isoagglutinins (antibodies that cause red blood cells to clump together) in healthy subjects.
* To study the frequency of these effects and determine whether there is a dose-response relationship with probiotics and isoagglutinin titers.

Eligibility:

* Healthy adults, 18 years or older, with type A, B, or O blood.
* Female participants need to have undergone menopause or have had a hysterectomy.
* Individuals are ineligible if they currently donate platelets; have a history of ulcerative colitis or Crohn s disease; have had major bowel surgery; are pregnant or capable of becoming pregnant; have a bleeding or clotting disorder; have a history of a blood disorder or immune deficiency; have a history of high-risk behaviors for exposure to HIV or hepatitis B or C; have diabetes; have received vaccinations in the past 2 months, with the exception of the flu vaccine; are currently taking immunosuppressive medications; are currently taking antibiotics; or have taken probiotic supplements within the last 12 months.

Design:

* Researchers will conduct the following tests throughout the 28-week study:

* Blood samples will be drawn every 2 weeks to measure the quantity of isoagglutinin titers.
* Depending on individual results, continued blood testing may be done every 3 months for 1 year, then every 6 to 12 months for up to 5 years.
* Study subjects will take a probiotic supplement at a dose of 1 to 3 caplets per day for 18 consecutive weeks according to the following schedule:

* During the first 6-week period, the subject will take one probiotic tablet daily.
* During the second 6-week period, the subject will take one probiotic tablet twice daily.
* During the third 6-week period, the subject will take one probiotic tablet three times daily.
* Control group subjects will be followed in a similar manner but will not take probiotic supplements.
* The outcome measure is the percent of probiotic ingestors (the study subjects) versus control group subjects who experience a fourfold or greater rise in isoagglutinin titer.
* Study subjects will receive the following financial compensation: $10 per blood sample, for a maximum of $240 if all 24 samples are collected; $100 after completing the first 6-week period; $150 after completing the second 6-week period; and $200 after completing the third 6-week period.
* Control subjects will receive $10 per blood sample, for a maximum of $150 if all 15 samples are collected.

Conditions

  • Isoagglutinin-Mediated Hemolysis
  • Probiotic Toxicity

Interventions

DIETARY_SUPPLEMENT

Probiotic Supplement

Sponsors & Collaborators

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Susan F Leitman, M.D. · National Institutes of Health Clinical Center (CC)

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-28
Primary Completion
2011-04-06
Completion
2011-04-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891787 on ClinicalTrials.gov